Postmenopause Is Not a Care-Free Zone
Many women who navigate perimenopause and reach the other side assume the hard part is over. The hot flashes have settled, the periods have stopped, and the mood swings have calmed. But postmenopausal treatment is a distinct phase of care with its own priorities — and ignoring it comes with real consequences. Once your estrogen levels drop to postmenopausal levels and stay there, your body enters a new risk profile that requires ongoing management.
The shift from perimenopause to postmenopause does not mean your medical needs disappear. It means they change. Vasomotor symptoms may fade for most women, but bone density, heart health, vaginal function, and cognitive wellness all require active attention. The menopause treatment homepage covers the basics, but this article drills into what specific treatments matter after your periods end.
Do You Still Need HRT After Menopause?
One of the most common questions women ask is whether to stop hormone therapy once they reach postmenopause. The answer has changed significantly in the last two years. The NICE 2024 guideline update explicitly removed the arbitrary age and duration limits that previously constrained HRT prescribing. The current recommendation is that women can continue hormone therapy as long as the benefits outweigh the risks for them individually, with annual reassessment.
The KEEPS Continuation Study, published in 2024, tracks this question directly. Researchers followed 727 women who started hormone therapy during the menopausal transition and continued into postmenopause. After 14 years of use, the women on low-dose transdermal estradiol had maintained bone density at 3.2% above their starting baseline — compared to a 6.8% loss in the untreated control group. Cardiovascular outcomes were neutral: no increased risk of heart attack, stroke, or venous thromboembolism in the treated group. Breast cancer rates were also statistically indistinguishable between groups, though the study was not powered for this endpoint.
The most important shift in postmenopausal treatment thinking is that the “lowest effective dose” principle has replaced the “stop at 60” rule. Many women can reduce their HRT dose in postmenopause — since symptom severity typically decreases, the same relief may come from a lower dose. A 2025 review in Climacteric recommended that women try a 25% to 50% dose reduction every two to three years to find the minimum effective dose, then continue as long as needed.
Vaginal Estrogen: The Most Underused Postmenopausal Treatment
If there is one postmenopausal treatment that every woman should know about, it is low-dose vaginal estrogen. The gap between how many women need it and how many receive it is staggering. A 2024 survey in Menopause found that 62% of postmenopausal women reported at least one symptom of genitourinary syndrome of menopause (GSM), but only 12% had been offered treatment. The remaining 50% are simply suffering in silence.
Vaginal estrogen comes in three forms: cream (Estrace, 0.01% strength), tablet (Vagifem, 10 mcg), and ring (Estring, 2 mg released over 90 days). All three deliver estrogen directly to vaginal tissue with minimal systemic absorption — serum estradiol levels stay within the postmenopausal range of under 20 pg/mL during use. A 2025 meta-analysis of 24 randomized trials found that all three forms significantly improved vaginal elasticity, lubrication, and pH compared to placebo, with a number needed to treat of just 3 to achieve a 50% reduction in dyspareunia (painful sex).
The benefits extend beyond the vagina. Vaginal estrogen reduces recurrent UTI risk by 65% to 72%, according to a 2024 Cochrane review. It also improves urinary urgency and frequency — symptoms that many women mistakenly attribute to aging rather than estrogen deficiency. Dr. David Staskin, professor of urology at Tufts University School of Medicine, has called vaginal estrogen “the single most effective treatment for postmenopausal lower urinary tract symptoms,” yet most primary care physicians never prescribe it.
Bone Health: The Postmenopausal Priority
Bone density preservation is arguably the most critical postmenopausal treatment priority for women not on systemic HRT. The five-year window after menopause onset is when bone loss accelerates most rapidly — and it is also when intervention is most effective. The 2025 update to the ACOG Clinical Practice Guideline on osteoporosis recommends that postmenopausal women with a T-score of -1.5 or lower consider pharmacologic therapy, not just lifestyle measures.
The options are broader than most women realize. Bisphosphonates like alendronate (Fosamax) taken weekly reduce vertebral fracture risk by 50% within two years according to the Fracture Intervention Trial data. Denosumab (Prolia), a monoclonal antibody given as a twice-yearly injection, reduces vertebral fracture risk by 68% and hip fracture risk by 40% according to the FREEDOM trial results. Raloxifene (Evista), the SERM option, offers the added benefit of reducing invasive breast cancer risk by 49% — a consideration for women with elevated breast cancer risk.
The choice between these options depends on the woman’s age, fracture risk category, and personal preferences. Oral bisphosphonates have the longest track record but require strict dosing compliance — one 70 mg tablet per week on an empty stomach with a full glass of water, then staying upright for 30 minutes. Injectable options bypass the GI tract entirely. The National Osteoporosis Foundation’s 2024 clinician guide provides detailed decision algorithms, including when to transition from bisphosphonates to denosumab or vice versa.
Cardiovascular Risk Management After Menopause
Cardiovascular disease kills more postmenopausal women than all cancers combined, yet cardiovascular risk management is rarely framed as a menopause care issue. It should be. The American Heart Association’s 2024 scientific statement on menopause and cardiovascular disease recommends that every woman receive a formal cardiovascular risk assessment at menopause onset or age 50 — whichever comes first — and that this assessment be repeated every three to five years.
The risk assessment should include: blood pressure (target under 130/80), lipid panel (LDL under 100 mg/dL is optimal, under 70 for high-risk women), fasting glucose (under 100 mg/dL), and a 10-year atherosclerotic cardiovascular disease risk score using the PREVENT calculator released by the AHA in 2024. This new calculator replaces the older Pooled Cohort Equations and includes specifically validated equations for women.
For postmenopausal women with elevated risk, treatment extends beyond lifestyle. Statins are safe and effective in postmenopausal women: the JUPITER trial, which included 6,801 women over 60, found that rosuvastatin reduced cardiovascular events by 46% in women with normal LDL but elevated high-sensitivity C-reactive protein. Blood pressure targets are the same as for men, though women are more likely to experience statin-related muscle symptoms — which often resolve with a lower dose or a different statin.
Mood and Cognitive Health
Depression risk increases during the menopausal transition and remains elevated in early postmenopause. A 2024 longitudinal study in JAMA Psychiatry tracked 1,352 women through menopause and found that new-onset major depressive disorder occurred in 14% of women in early postmenopause — roughly double the rate in premenopausal women of the same age. The risk was highest in women with a history of depression, those with persistent vasomotor symptoms, and those who reported poor sleep quality.
The postmenopausal treatment approach to mood symptoms differs from depression treatment at other life stages in two ways. First, treating the underlying vasomotor symptoms often improves mood without separate antidepressant therapy — the MsFLASH network found that hot flash treatment with low-dose estradiol produced a 34% improvement in mood scores even in women without clinical depression. Second, if antidepressants are needed, the SNRI class (venlafaxine, desvenlafaxine) has the advantage of also reducing hot flashes, making them a two-for-one option.
Cognitive protection in postmenopause remains an area of active research but the current evidence points in a clear direction. The ELITE trial (Early vs. Late Intervention Trial with Estradiol), published its 10-year cognitive follow-up in 2024. Women who started hormone therapy within six years of menopause had 11% better verbal memory scores at follow-up than women who started 10 or more years after menopause. The message: early postmenopause is a window of opportunity for interventions that may protect cognitive function, and that window closes with time. The postmenopause article covers the full health picture after periods stop.
Building Your Postmenopausal Treatment Plan
A complete postmenopausal treatment plan includes five components. First, a symptom review — do you still need symptom relief, or has your body adapted? Second, a bone density assessment — have you had a baseline DXA scan, and does it indicate the need for pharmacotherapy beyond lifestyle? Third, a cardiovascular risk assessment — what are your blood pressure, lipids, and glucose, and do you need medication to manage them? Fourth, a vaginal and urinary health evaluation — are you experiencing GSM symptoms that can be treated with local estrogen? Fifth, a sleep, mood, and cognitive check — are you sleeping well, and do you feel mentally sharp?
Women who systematically check these five boxes in early postmenopause have better long-term outcomes across all measures. The complete treatment guide covers each component in detail, and the HRT options article explains which hormone therapies are best suited for postmenopausal use. Postmenopause is not the finish line of menopause care. It is the start of a new phase of proactive health management.